Medline (NASDAQ:MDLN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Medline (NASDAQ:MDLN) had its price objective lifted by research analysts at BMO Capital Markets from $45.00 to $54.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price target would suggest a potential upside of 8.87% from the stock’s current price.

A number of other brokerages have also commented on MDLN. Bank of America initiated coverage on shares of Medline in a research report on Monday, January 12th. They issued a “buy” rating and a $50.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Medline in a research note on Monday, January 12th. They issued a “buy” rating and a $49.00 price target on the stock. Rothschild & Co Redburn set a $42.00 price objective on shares of Medline in a research note on Monday, January 12th. Mizuho began coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, UBS Group started coverage on Medline in a report on Monday, January 12th. They set a “buy” rating and a $48.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.35.

Medline Price Performance

Shares of MDLN traded up $1.42 during midday trading on Thursday, hitting $49.60. The stock had a trading volume of 1,448,358 shares, compared to its average volume of 3,330,101. The firm has a 50 day moving average of $44.21. Medline has a twelve month low of $34.89 and a twelve month high of $50.88.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The company had revenue of $7.79 billion during the quarter, compared to analyst estimates of $7.52 billion. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year.

Insider Buying and Selling

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the transaction, the insider owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the purchase, the director directly owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Hedge Funds Weigh In On Medline

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDLN. Sound Income Strategies LLC bought a new position in shares of Medline in the fourth quarter valued at about $25,000. Entrust Financial LLC bought a new stake in shares of Medline during the 4th quarter worth about $26,000. NBC Securities Inc. acquired a new position in Medline in the 4th quarter valued at about $28,000. Global Retirement Partners LLC bought a new position in Medline in the 4th quarter valued at about $31,000. Finally, North Star Investment Management Corp. acquired a new stake in Medline during the fourth quarter worth approximately $36,000.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Revenue and growth beat — Q4 net sales of ~$7.8B (+14.8% YoY) topped estimates and full‑year 2025 sales were $28.4B; organic sales growth and volume gains across Medline Brand and Supply Chain Solutions underpin confidence in demand. Read More.
• Positive Sentiment: Upbeat 2026 guidance and customer momentum — management guided to 8–9% organic sales growth and $3.5–$3.6B adjusted EBITDA for 2026 and highlighted $2.4B of new customer signings in 2025, supporting forward revenue visibility. Read More.
• Positive Sentiment: Strong cash generation and improved leverage — operating cash of ~$1.7B and free cash flow of ~$1.3B in 2025, plus net leverage down (net debt/EBITDA improved), reduce financing risk and support reinvestment. Read More.
• Neutral Sentiment: Successful IPO completed — listing provides capital and public-market liquidity; supports longer-term investment but also introduced one-time public-company costs. Read More.
• Neutral Sentiment: Analyst/institutional interest — multiple buy/outperform ratings and heavy institutional allocations noted; positive for liquidity and sentiment but increases focus on near-term execution vs. elevated expectations. Read More.
• Negative Sentiment: Earnings miss and profit squeeze — GAAP EPS was roughly break-even / ($0.01), missing street EPS expectations; Q4 net income fell ~37.7% YoY to $180M due to higher COGS, tariffs and IPO/headcount expenses. Read More.
• Negative Sentiment: Margin pressure from tariffs and investments — management flagged higher costs of goods sold, tariffs and operating investments that compressed margins; adjusted EBITDA was roughly flat vs. prior year despite strong sales. Read More.
• Negative Sentiment: Execution watch — as a newly public company, investors will focus on whether Medline converts the sales momentum into margin recovery and meets 2026 adjusted EBITDA targets; valuation/expectations articles highlight the need for clarity. Read More.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.